We want raw data, now

  title={We want raw data, now},
  author={F. Godlee},
  journal={BMJ : British Medical Journal},
  • F. Godlee
  • Published 2009
  • Medicine
  • BMJ : British Medical Journal
This week’s BMJ is dominated by a cluster of articles on oseltamivir (Tamiflu) (doi:10.1136/bmj.b5351, doi:10.1136/bmj.b5387, doi:10.1136/bmj.b5106, doi:10.1136/bmj.b5164, doi:10.1136/bmj.b5248, doi:10.1136/bmj.b5364). Between them the articles conclude that the evidence that oseltamivir reduces complications in otherwise healthy people with pandemic influenza is now uncertain and that we need a radical change in the rules on access to trial data. Briefly, in updating their Cochrane review… Expand
ArmAcI: le nuove norme emA drug data access: the new emA policy
Ethical and scientific arguments in favour of sharing clinical trial data are closely entwined. Here we analyse the key elements needed to facilitate public scrutiny and secondary analysis of theseExpand
[The putative link between the MMR vaccine and autism and refusal to vaccinate].
This episode invites to think about the credibility and trust in the authorities and professionals to the population, as well as the suspicions that may arise when there are potential conflicts of interest among professionals, industry magazines and the population. Expand
Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review
Routine long term implementation of some of the measures to interrupt or reduce the spread of respiratory viruses might be difficult, however, many simple and low cost interventions reduce the transmission of epidemic respiratory viruses. Expand
Industry sponsorship and research outcome: systematic review with meta-analysis
Drug and device studiessponsored by manufacturing companies have more favorable efficacy results and conclusions than studies sponsored by other sources, compared with studies having other sources of sponsorship. Expand
Industry sponsorship and research outcome.
The analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments. Expand
The crisis in Cochrane: Evidence Debased Medicine.
  • D. Healy
  • Medicine, Psychology
  • Indian journal of medical ethics
  • 2019
This essay looks at the crisis in the context of the disastrous effects of medication for paediatric depression on children as a consequence of the suppression of adverse findings from clinical trials. Expand
Clinician should include swine flu influenza A in the differential diagnosis of the patients presented with febrile respiratory illness who have been in contact, or visit the community having positive cases of influenza. Expand
Sharing clinical trial data: maximizing benefits, minimizing risk.
It is concluded that sharing data is in the public interest, but a multi-stakeholder effort is needed to develop a culture, infrastructure, and policies that will foster responsible sharing—now and in the future. Expand
Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
Objective To investigate to what extent three types of documents for reporting clinical trials provide sufficient information for trial evaluation. Design Retrospective analysis Data sources PrimaryExpand
Peering into the “rabbit hole” of publication bias and inadequate research transparency: Adding tangibility to the abstract
A “case series” of these detrimental issues in action is presented in an effort to emphasize the tangibility of these issues and thereby help make their importance unmistakably clear. Expand